Galmic

Galmic was developed to convert the first-generation galanin agonist galnon into a more drug-like scaffold. Investigators took galnon's presumed tripeptidomimetic pharmacophores and displayed them on a rigid macrocyclic framework related to marine natural products, so that three functional groups are presented near one another in space in a way reminiscent of a protein surface ^[1]. Screening a small synthetic library identified galmic, which binds GalR1 with micromolar affinity (Ki around 34 micromolar) and shows essentially no affinity for GalR2, giving it a GalR1-biased profile ^[1].

Functionally, galmic reproduces galanin's central actions. Like galanin it suppresses long-term potentiation in the dentate gyrus, and it blocks status epilepticus whether injected directly into the hippocampus or given intraperitoneally, confirming systemic activity ^[1][2]. In behavioral assays it produces antidepressant-like effects in the forced-swim test and is a potent inhibitor of flinching behavior in the formalin model of inflammatory pain, extending the galaninergic target concept from seizures into mood and nociception ^[1]. Electrophysiological comparison confirmed that galmic, galnon, and galanin all attenuate dentate gyrus potentiation to a similar degree ^[2].

The total synthesis of galmic, including its oxazole precursors and a macrolactamization step, was reported separately, underscoring that this was a deliberately engineered macrocycle rather than a fortuitous screening hit ^[3]. Galmic is significant less as a candidate drug than as a demonstration that a rigid, protein-surface-mimicking small molecule can recapitulate the in vivo pharmacology of a neuropeptide, informing later peptidomimetic design.

Galmic has only been studied in rodents and has no human safety data. Its GalR1 preference means galanin-associated metabolic effects, such as altered glucose handling, are plausible at active doses, though this was not a focus of the original work. Its micromolar potency implies relatively high required exposures, and no formal toxicology has been published. It should be treated as a laboratory tool compound.

Galmic was reported in 2004 by Bartfai, Rebek, and colleagues at The Scripps Research Institute as a second-generation nonpeptide galanin agonist, together with a companion paper describing its total synthesis. The design philosophy was to use a rigid macrocycle capable of imitating a protein surface, a concept drawn from Rebek's work on synthetic receptors and marine-natural-product-like scaffolds. It followed directly from the galnon proof of concept and was intended to provide a cleaner, more drug-like galanin agonist.

Galmic is respected in medicinal chemistry as an elegant example of protein-surface mimicry applied to a neuropeptide target, and it reinforced the therapeutic promise of galanin receptors in epilepsy, depression, and pain. It never entered development and, like galnon, has been superseded in the anticonvulsant space by systemically active peptidic analogs. It is unknown outside academic literature and unavailable commercially.